| 1 |
35081882 | Process Development for the Production and Purification of PEGylated RhG-CSF Expressed in Escherichia coli. | 2022 |
5 |
| 2 |
32827162 | Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy. | 2021 Feb |
2 |
| 3 |
33039551 | Process analytical technology application for protein PEGylation using near infrared spectroscopy: G-CSF as a case study. | 2021 Jan 10 |
1 |
| 4 |
33590721 | Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. | 2021 Apr |
1 |
| 5 |
33880064 | Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic. | 2021 |
1 |
| 6 |
34900145 | Production of PEGylated GCSF from Non-classical Inclusion Bodies Expressed in Escherichia coli. | 2021 Oct-Dec |
4 |
| 7 |
32476162 | Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial. | 2020 Aug |
1 |
| 8 |
32687956 | Development of an integrated continuous PEGylation and purification Process for granulocyte colony stimulating factor. | 2020 Oct 10 |
1 |
| 9 |
32879214 | Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism. | 2020 |
2 |
| 10 |
33330413 | Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity. | 2020 |
1 |
| 11 |
29963237 | Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. | 2018 Jun 12 |
3 |
| 12 |
30043207 | Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer. | 2018 Oct |
1 |
| 13 |
28721592 | Construction, Purification, and Characterization of a Homodimeric Granulocyte Colony-Stimulating Factor. | 2017 Oct |
2 |
| 14 |
28870643 | Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. | 2017 Dec |
2 |
| 15 |
29108384 | Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients. | 2017 Oct 3 |
2 |
| 16 |
29237905 | A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy. | 2017 |
2 |
| 17 |
27073670 | Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. | 2016 Apr |
1 |
| 18 |
25407640 | Chemical modifications of therapeutic proteins induced by residual ethylene oxide. | 2015 Feb |
2 |
| 19 |
25450254 | Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. | 2015 Jan |
8 |
| 20 |
26254266 | G-CSF and GM-CSF in Neutropenia. | 2015 Aug 15 |
1 |
| 21 |
26308166 | Site-specific characterization and absolute quantification of pegfilgrastim oxidation by top-down high-performance liquid chromatography-mass spectrometry. | 2015 Sep 15 |
1 |
| 22 |
24308604 | A direct-infusion- and HPLC-ESI-Orbitrap-MS approach for the characterization of intact PEGylated proteins. | 2014 Jan 7 |
3 |
| 23 |
24474639 | Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. | 2014 Mar |
2 |
| 24 |
24597960 | Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. | 2014 Jun |
2 |
| 25 |
24083590 | Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. | 2013 Nov |
1 |
| 26 |
23342488 | [Recombinant granulocyte-colony stimulating factor (filgrastim): optimization of conjugation with polyethylene glycol]. | 2012 Sep-Oct |
2 |
| 27 |
21456630 | Pharmacokinetics and pharmacodynamics of pegfilgrastim. | 2011 May |
1 |
| 28 |
20361316 | Capillary electrophoretic separation of poly(ethylene glycol)-modified granulocyte-colony stimulating factor. | 2010 Mar |
11 |
| 29 |
20945411 | Application of microchip CGE for the analysis of PEG-modified recombinant human granulocyte-colony stimulating factors. | 2010 Nov |
3 |
| 30 |
19308043 | Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. | 2009 May |
2 |
| 31 |
19469471 | Tailored PEG for rh-G-CSF analogue site-specific conjugation. | 2009 Jun |
1 |
| 32 |
18719223 | Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates. | 2008 Nov |
1 |
| 33 |
17339136 | Effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor (Cys17Ser) in aqueous two-phase systems containing chelated metal ions. | 2007 Jun 1 |
3 |
| 34 |
17941684 | Site-specific pegylation of G-CSF by reversible denaturation. | 2007 Nov-Dec |
3 |
| 35 |
17970641 | Agents under investigation for the treatment and prevention of neutropenia. | 2007 Nov |
4 |
| 36 |
16441592 | A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. | 2006 Feb |
1 |
| 37 |
16597829 | Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. | 2006 May |
7 |
| 38 |
16737933 | Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. | 2006 Jun |
1 |
| 39 |
17155894 | Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. | 2006 Dec |
1 |
| 40 |
17176123 | Effects of site-specific polyethylene glycol modification of recombinant human granulocyte colony-stimulating factor on its biologic activities. | 2006 |
1 |
| 41 |
15531906 | Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. | 2005 Jan |
1 |
| 42 |
16392893 | Spotlight on pegfilgrastim in chemotherapy-induced neutropenia. | 2005 |
2 |
| 43 |
12488547 | Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. | 2003 Jan |
1 |
| 44 |
12650998 | Mutation of surface-exposed histidine residues of recombinant human granulocyte-colony stimulating factor (Cys17Ser) impacts on interaction with chelated metal ions and refolding in aqueous two-phase systems. | 2003 Mar 25 |
2 |
| 45 |
12790662 | Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. | 2003 May-Jun |
1 |
| 46 |
12921217 | Pharmacokinetics of pegfilgrastim. | 2003 Aug |
1 |
| 47 |
10661570 | Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. | 2000 |
3 |
| 48 |
9450813 | Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). | 1998 Jan |
1 |
| 49 |
10051965 | Effect of divalent polyethylene glycol units, conjugated on human granulocyte colony-stimulating factor, on biological activities in vitro and in vivo. | 1998 |
3 |
| 50 |
8668656 | Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). | 1996 Jan |
2 |